Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function

European Journal of Cardio-thoracic Surgery

Volumn 36, Issue 6, 2009, Pages 1024-1030

  Kolseth, Solveig Moss ^a   Nordhaug, Dag Ole ^a,b   Stenseth, Roar ^a,b   Sellevold, Olav ^a,b   Kirkeby Garstad, Idar ^a   Wahba, Alexander ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adrenergic beta agonists; Cardiac surgery; Haemodynamics; Heart failure; Left ventricular function; Levosimendan

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; DOBUTAMINE; DOPAMINE; INOTROPIC AGENT; LEVOSIMENDAN; NORADRENALIN;

ADULT; AGED; AORTA BALLOON; ARTERIAL PRESSURE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD PRESSURE MONITORING; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY HEMODYNAMICS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HEART STROKE VOLUME; HEART VENTRICULOGRAPHY; HUMAN; INTENSIVE CARE UNIT; MALE; MORTALITY; OXYGEN SATURATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

AGED; CARDIOPULMONARY BYPASS; CARDIOTONIC AGENTS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; NOREPINEPHRINE; PHOSPHODIESTERASE INHIBITORS; PREANESTHETIC MEDICATION; PYRIDAZINES; RETROSPECTIVE STUDIES; STROKE VOLUME; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70449535742     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2009.05.001     Document Type: Article

References (25)

1. Rooke G.A., and Feigl E.O. Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. Circ Res 50 (1982) 273-286
2. Thackray S., Easthaugh J., Freemantle N., and Cleland J.G. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 4 (2002) 515-529
3. O'Connor C.M., Gattis W.A., Uretsky B.F., Adams Jr. K.F., McNulty S.E., Grossman S.H., McKenna W.J., Zannad F., Swedberg K., Gheorghiade M., and Califf R.M. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138 (1999) 78-86
4. Fares W.H. Management of acute decompensated heart failure in an evidence-based era: what is the evidence behind the current standard of care?. Heart Lung 37 (2008) 173-178
5. Takahashi R., Talukder M.A., and Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol 400 (2000) 103-112
6. Meyer K., Klocke R.C., Schipke J.D., Gams E., and Korbmacher B. Ca(2+) sensitizer superior to catecholamine during myocardial stunning?. Eur J Cardiothorac Surg 34 (2008) 326-331
7. Yokoshiki H., Katsube Y., Sunagawa M., Sperelakis N., and Levosimendan. a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 333 (1997) 249-259
8. 2 consumption in dogs. Am J Physiol Heart Circ Physiol 294 (2008) H238-248
9. De Luca L., Proietti P., Celotto A., Bucciarelli-Ducci C., Benedetti G., Di Roma A., Sardella G., Genuini I., and Fedele F. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J 150 (2005) 563-568
10. Das B., and Sarkar C. Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart model. Vascul Pharmacol 47 (2007) 248-256
11. du Toit E.F., Genis A., Opie L.H., Pollesello P., and Lochner A. A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol 154 (2008) 41-50
12. Labriola C., Siro-Brigiani M., Carrata F., Santangelo E., and Amantea B. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 42 (2004) 204-211
13. Akgul A., Mavioglu L., Katircioglu S.F., Pac M., and Cobanoglu A. Levosimendan for weaning from cardiopulmonary bypass after coronary artery bypass grafting. Heart Lung Circ 15 (2006) 320-324
14. Tokuda Y., Grant P.W., Wolfenden H.D., Manganas C., Lyon W.J., and Murala J.S. Levosimendan for patients with impaired left ventricular function undergoing cardiac surgery. Interactive Cardiovasc Thorac Surg 5 (2006) 322-326
15. Malliotakis P., Xenikakis T., Linardakis M., and Hassoulas J. Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: a case series. Hellenic J Cardiol 48 (2007) 80-88
16. Nijhawan N., Nicolosi A.C., Montgomery M.W., Aggarwal A., Pagel P.S., and Warltier D.C. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 34 (1999) 219-228
17. Lilleberg J., Nieminen M.S., Akkila J., Heikkila L., Kuitunen A., Lehtonen L., Verkkala K., Mattila S., and Salmenpera M. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 19 (1998) 660-668
18. Al-Shawaf E., Ayed A., Vislocky I., Radomir B., Dehrab N., and Tarazi R. Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anaesth 20 (2006) 353-357
19. De Hert S.G., Lorsomradee S., Cromheecke S., and Van der Linden P.J. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 104 (2007) 766-773
20. Tasouli A., Papadopoulos K., Antoniou T., Kriaras I., Stavridis G., Degiannis D., and Geroulanos S. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use. Eur J Cardiothorac Surg 32 (2007) 629-633
21. Siirila-Waris K., Suojaranta-Ylinen R., and Harjola V.P. Levosimendan in cardiac surgery. J Cardiothorac Vasc Anaesth 19 (2005) 345-349
22. Levin R., Degrange M., Porcile R., Salvagio F., and Botbol L.A. Abstract 3044: the preoperative utilization of levosimendan (preoperative optimization) reduced mortality and low output syndrome after cardiac surgery in patients with low ejection fraction (EF < 25%). Circulation 116 (2007) II_682
23. Braun J.P., Jasulaitis D., Moshirzadeh M., Doepfmer U.R., Kastrup M., von Heymann C., Dohmen P.M., Konertz W., and Spies C. Levosimendan may improve survival in patients requiring mechanical assist devices for post-cardiotomy heart failure. Crit Care 10 (2006) R17
24. Lehman A., Kiessling A., Isgro F., Zeitler C., Thaler E., and Bold J. Levosimendan in patients with acute myocardial ischemia undergoing emergency surgical revascularization. Eur J Anaesth 25 (2008) 224-229
25. Levin R.L., Degrange M.A., Porcile R., Salvagio F., Blanco N., Botbol A.L., Tanus E., and del Mazo C.D. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome. Rev Esp Cardiol 61 (2008) 471-479